» Articles » PMID: 19244619

A Non-apoptotic Role for Fas/FasL in Erythropoiesis

Overview
Journal FEBS Lett
Specialty Biochemistry
Date 2009 Feb 27
PMID 19244619
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Issues remain to be elucidated in the developmental regulation of erythropoiesis. In particular the role of Fas, a member of the tumor necrosis factor family of receptors despite much work remains unclear. During erythropoiesis, Fas is expressed at low levels on erythroblasts. For most cell types, Fas to FasL interaction causes apoptotic cell death via caspase activation. Here, we show that in humans, early erythroid progenitors are refractory to apoptosis triggered through Fas. Further during early human erythropoiesis, Fas triggered caspase activation provides a positive stimulus for erythroid maturation, and does not alter cellular proliferation or trigger apoptosis.

Citing Articles

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease.

Andrade J, Dalboni M, Clemente O, Silva B, Domingues B, Rodrigues A PLoS One. 2023; 18(6):e0286854.

PMID: 37390095 PMC: 10313056. DOI: 10.1371/journal.pone.0286854.


The accumulation of miR-125b-5p is indispensable for efficient erythroblast enucleation.

Fang F, Xu L, Liang L, Qu M, Yao H, Yue W Cell Death Dis. 2022; 13(10):886.

PMID: 36270980 PMC: 9586935. DOI: 10.1038/s41419-022-05331-5.


Role of Caspase-10-P13tBID axis in erythropoiesis regulation.

Lamarque M, Gautier E, Rodrigues F, Guillem F, Bayard E, Broussard C Cell Death Differ. 2022; 30(1):208-220.

PMID: 36202990 PMC: 9883265. DOI: 10.1038/s41418-022-01066-0.


Role of Extrinsic Apoptotic Signaling Pathway during Definitive Erythropoiesis in Normal Patients and in Patients with β-Thalassemia.

Raducka-Jaszul O, Boguslawska D, Jedruchniewicz N, Sikorski A Int J Mol Sci. 2020; 21(9).

PMID: 32397135 PMC: 7246929. DOI: 10.3390/ijms21093325.


Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.

Chiloff D, Candido de Almeida D, Dalboni M, Canziani M, George S, Morsi A Am J Physiol Renal Physiol. 2020; 318(4):F861-F869.

PMID: 32003597 PMC: 7474254. DOI: 10.1152/ajprenal.00433.2019.